82VS
AcceleratorPre-Seed–Seed · 14 people tracked
Investment thesis
82vs operates as a venture studio leveraging Alloy Therapeutics' discovery platforms and services to de-risk early-stage biotech company creation. Portfolio companies benefit from expert support in strategy, legal services, R&D funding, and pharma partnerships while avoiding the burden of building their own infrastructure, accelerating their path to Series A financing.
Source: firm website, verified Jul 21, 2026.
Team · 14 people
from the firm's websiteWhat they invest in
from 6 of 10 portfolio companiesBiotech ×5Healthtech ×4Medical Devices ×4AI & Machine Learning ×2Cloud Computing ×1Cybersecurity ×1Deep Tech ×1
HQs:United States×2
Investments · 10 tracked
founders shown can be your intro pathAakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.
BiotechHealthtechMedical Devices<UNKNOWN>
Hemanta Baruah(Founder & CEO)
Broadwing Bio develops antibody-based therapies targeting genetically validated ophthalmology conditions, particularly geographic atrophy and glaucoma, to preserve vision and prevent blindness. The company builds on naturally occurring genetic variants to create novel treatments for ocular diseases.
BiotechHealthtechMedical Devices
Not explicitly named(Founder, CEO)
Google is a technology company that provides tools and products designed with privacy, security, and responsible AI practices as foundational principles. Its services span communication, productivity, and AI-powered applications, all protected by advanced security infrastructure.
AI & Machine LearningCloud ComputingCybersecurity
Overture develops precision antibody therapeutics for obesity treatment, targeting metabolic dysfunction pathways to reduce fat mass while preserving lean muscle through monthly-dosed therapeutic approaches.
BiotechHealthtechMedical Devices
Alloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
AI & Machine LearningBiotechDeep TechHealthtechWaltham, US
Tillman Gerngross(Founder, CEO, Chairman)
Voro Therapeutics develops tumor-activated biologics, specifically an antibody-based platform called PrimeBody™, designed to treat cancers including colorectal, gastric, prostate, and lung cancers while minimizing systemic toxicity. The company leverages masking technology and conditionally activated linkers to enable systemic delivery with tumor-specific activation.
BiotechMedical DevicesSan Diego, US
Frequently asked questions
- What stage does 82VS invest at?
- 82VS invests at the Pre-Seed, Seed stages.
- What sectors does 82VS focus on?
- 82VS focuses on Biotech.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Boundary Capital invests in high-growth private technology companies focused on positive impact across life sciences, AI, and engineering sectors.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
Canaan is an early-stage venture capital firm investing in transformative entrepreneurs across healthcare, consumer technology, and deep tech sectors.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.